
Precision Risk Reduction in ASCVD: Targeting LDL-C, Lp(a), and Inflammation
STATEMENT OF NEED Cardiovascular disease remains the leading cause of mortality in the US, claiming a life every 34 seconds. Despite effective therapies for atherosclerotic cardiovascular disease (ASCVD), 25.5% of US adults have high low-density lipoprotein cholesterol (LDL-C) with up to 45% of…
- Price
- Free
- Accredited provider:
- i3 Health
- Learning platform:
- IQ Apparatus
- Release date
- November 19, 2026
- Expires
- November 19, 2027